Clioquinol induces DNA double-strand breaks, activation of ATM, and subsequent activation of p53 signaling

Toxicology

Volumn 299, Issue 1, 2012, Pages 55-59

  Katsuyama, Masato ^a   Iwata, Kazumi ^a   Ibi, Masakazu ^a   Matsuno, Kuniharu ^a   Matsumoto, Misaki ^a   Yabe Nishimura, Chihiro ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

Author keywords

ATM; Clioquinol; Neurotoxicity; P53; SMON

Indexed keywords

2 MORPHOLINO 6 (1 THIANTHRENYL) 4 PYRANONE; ATM PROTEIN; CLIOQUINOL; DOUBLE STRANDED DNA; HISTONE H2AX; MESSENGER RNA; PROTEIN P21; PROTEIN P53;

ARTICLE; DOUBLE STRANDED DNA BREAK; ENZYME ACTIVATION; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL; NEUROTOXICITY; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CELL CYCLE PROTEINS; CELL LINE, TUMOR; CHROMONES; CLIOQUINOL; DNA BREAKS, DOUBLE-STRANDED; DNA-BINDING PROTEINS; HUMANS; MORPHOLINES; NEUROBLASTOMA; NEUROTOXICITY SYNDROMES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; PYRONES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS;

ATAXIA TELANGIECTASIA;

EID: 84862307896     PISSN: 0300483X     EISSN: 18793185     Source Type: Journal    
DOI: 10.1016/j.tox.2012.05.013     Document Type: Article

References (32)

1. Adlard P.A., Cherny R.A., Finkelstein D.I., Gautier E., Robb E., Cortes M., Volitakis I., Liu X., Smith J.P., Perez K., Laughton K., Li Q.X., Charman S.A., Nicolazzo J.A., Wilkins S., Deleva K., Lynch T., Kok G., Ritchie C.W., Tanzi R.E., Cappai R., Masters C.L., Barnham K.J., Bush A.I. Rapid restoration of cognition in Alzheimer's transgenic mice with 8-hydroxy quinoline analogs is associated with decreased interstitial Abeta. Neuron 2008, 59:43-55.
2. 2+. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:8374-8379.
3. Asakura K., Ueda A., Kawamura N., Ueda M., Mihara T., Mutoh T. Clioquinol inhibits NGF-induced Trk autophosphorylation and neurite outgrowth in PC12 cells. Brain Res. 2009, 1301:110-115.
4. Bakkenist C.J., Kastan M.B. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003, 421:499-506.
5. Benvenisti-Zarom L., Chen J., Regan R.F. The oxidative neurotoxicity of clioquinol. Neuropharmacology 2005, 49:687-694.
6. Cahoon L. The curious case of clioquinol. Nat. Med. 2009, 15:356-359.
7. Cater M.A., Haupt Y. Clioquinol induces cytoplasmic clearance of the X-linked inhibitor of apoptosis protein (XIAP): therapeutic indication for prostate cancer. Biochem. J. 2011, 436:481-491.
8. Cherny R.A., Atwood C.S., Xilinas M.E., Gray D.N., Jones W.D., McLean C.A., Barnham K.J., Volitakis I., Fraser F.W., Kim Y., Huang X., Goldstein L.E., Moir R.D., Lim J.T., Beyreuther K., Zheng H., Tanzi R.E., Masters C.L., Bush A.I. Treatment with a copper-zinc chelator markedly and rapidly inhibits beta-amyloid accumulation in Alzheimer's disease transgenic mice. Neuron 2001, 30:665-676.
9. Choi S.M., Choi K.O., Park Y.K., Cho H., Yang E.G., Park H. Clioquinol, a Cu(II)/Zn(II) chelator, inhibits both ubiquitination and asparagine hydroxylation of hypoxia-inducible factor-1alpha, leading to expression of vascular endothelial growth factor and erythropoietin in normoxic cells. J. Biol. Chem. 2006, 281:34056-34063.
10. Ding W.Q., Liu B., Vaught J.L., Yamauchi H., Lind S.E. Anticancer activity of the antibiotic clioquinol. Cancer Res. 2005, 65:3389-3395.
11. Egashira Y., Matsuyama H. Subacute myelo-optico-neuropathy (SMON) in Japan. With special reference to the autopsy cases. Acta Pathol. Jpn. 1982, 32(Suppl. 1):101-116.
12. Fan C., Katsuyama M., Nishinaka T., Yabe-Nishimura C. Transactivation of the EGF receptor and a PI3 kinase-ATF-1 pathway is involved in the upregulation of NOX1, a catalytic subunit of NADPH oxidase. FEBS Lett. 2005, 579:1301-1305.
13. Faux N.G., Ritchie C.W., Gunn A., Rembach A., Tsatsanis A., Bedo J., Harrison J., Lannfelt L., Blennow K., Zetterberg H., Ingelsson M., Masters C.L., Tanzi R.E., Cummings J.L., Herd C.M., Bush A.I. PBT2 rapidly improves cognition in Alzheimer's Disease: additional phase II analyses. J. Alzheimers Dis. 2010, 20:509-516.
14. Guo Z., Kozlov S., Lavin M.F., Person M.D., Paull T.T. ATM activation by oxidative stress. Science 2010, 330:517-521.
15. Huang J., Yang J., Maity B., Mayuzumi D., Fisher R.A. Regulator of G protein signaling 6 (RGS6) mediates doxorubicin-induced ATM and p53 activation by a reactive oxygen species-dependent mechanism. Cancer Res. 2011, 71:6310-6319.
16. Jack D.B., Riess W. Pharmacokinetics of iodochlorhydroxyquin in man. J. Pharm. Sci. 1973, 62:1929-1932.
17. Katsuyama M., Fan C., Arakawa N., Nishinaka T., Miyagishi M., Taira K., Yabe-Nishimura C. Essential role of ATF-1 in induction of NOX1, a catalytic subunit of NADPH oxidase: involvement of mitochondrial respiratory chain. Biochem. J. 2005, 386:255-261.
18. Kaur D., Yantiri F., Rajagopalan S., Kumar J., Mo J.Q., Boonplueang R., Viswanath V., Jacobs R., Yang L., Beal M.F., DiMonte D., Volitaskis I., Ellerby L., Cherny R.A., Bush A.I., Andersen J.K. Genetic or pharmacological iron chelation prevents MPTP-induced neurotoxicity in vivo: a novel therapy for Parkinson's disease. Neuron 2003, 37:899-909.
19. Kitagawa R., Bakkenist C.J., McKinnon P.J., Kastan M.B. Phosphorylation of SMC1 is a critical downstream event in the ATM-NBS1-BRCA1 pathway. Genes Dev. 2004, 18:1423-1438.
20. Kruse J.P., Gu W. Modes of p53 regulation. Cell 2009, 137:609-622.
21. Lannfelt L., Blennow K., Zetterberg H., Batsman S., Ames D., Harrison J., Masters C.L., Targum S., Bush A.I., Murdoch R., Wilson J., Ritchie C.W. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2008, 7:779-786.
22. Mao X., Li X., Sprangers R., Wang X., Venugopal A., Wood T., Zhang Y., Kuntz D.A., Coe E., Trudel S., Rose D., Batey R.A., Kay L.E., Schimmer A.D. Clioquinol inhibits the proteasome and displays preclinical activity in leukemia and myeloma. Leukemia 2009, 23:585-590.
23. McKinnon P.J. ATM and ataxia telangiectasia. EMBO Rep. 2004, 5:772-776.
24. Nakae K., Yamamoto S., Shigematsu I., Kono R. Relation between subacute myelo-optic neuropathy (S.M.O.N.) and clioquinol: nationwide survey. Lancet 1973, 1:171-173.
25. Nguyen T., Hamby A., Massa S.M. Clioquinol down-regulates mutant huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11840-11845.
26. Ritchie C.W., Bush A.I., Mackinnon A., Macfarlane S., Mastwyk M., MacGregor L., Kiers L., Cherny R., Li Q.X., Tammer A., Carrington D., Mavros C., Volitakis I., Xilinas M., Ames D., Davis S., Beyreuther K., Tanzi R.E., Masters C.L. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch. Neurol. 2003, 60:1685-1691.
27. Rohde W., Mikelens P., Jackson J., Blackman J., Whitcher J., Levinson W. Hydroxyquinolines inhibit ribonucleic acid-dependent deoxyribonucleic acid polymerase and inactivate Rous sarcoma virus and herpes simplex virus. Antimicrob. Agents Chemother. 1976, 10:234-240.
28. She Q.B., Chen N., Dong Z. ERKs and p38 kinase phosphorylate p53 protein at serine 15 in response to UV radiation. J. Biol. Chem. 2000, 275:20444-20449.
29. Takeda A., Takada S., Ando M., Itagaki K., Tamano H., Suzuki M., Iwaki H., Oku N. Impairment of recognition memory and hippocampal long-term potentiation after acute exposure to clioquinol. Neuroscience 2010, 171:443-450.
30. Tateishi J. Subacute myelo-optico-neuropathy: clioquinol intoxication in humans and animals. Neuropathology 2000, 20(Suppl.):S20-S24.
31. Tsubaki T., Honma Y., Hoshi M. Neurological syndrome associated with clioquinol. Lancet 1971, 1:696-697.
32. Wang Y., Branicky R., Stepanyan Z., Carroll M., Guimond M.P., Hihi A., Hayes S., McBride K., Hekimi S. The anti-neurodegeneration drug clioquinol inhibits the aging-associated protein CLK-1. J. Biol. Chem. 2009, 284:314-323.